Twist Bioscience Corporation

TWST ·Healthcare, Drug Manufacturers - General, United States
Financial Statements Cash Flow Statement
Annual Quarterly

Cash Flow Statement

Line Item FY2025 FY2024 FY2023 FY2022 FY2021 FY2020 FY2019 FY2018
Operating Activities
Net Income $-77.7M $-208.7M $-204.6M $-217.9M $-152.1M $-139.9M $-107.7M $-71.2M
Depreciation & Amortization $24.9M $31.4M $29.3M $16.5M $9.8M $6.7M $6.1M $5.7M
Depreciation $23.8M $27.3M $24.1M
Amortization $1.1M $4.1M $5.3M $4.9M $500.0K $200.0K
Stock-Based Compensation $64.5M $50.9M $30.3M $79.7M $37.0M $17.1M $11.2M $3.0M
Net Cash from Operating Activities $-47.6M $-64.1M $-142.5M $-124.4M $-112.2M $-142.3M $-87.9M $-66.2M
Investing Activities
Capital Expenditures $28.0M $5.1M $27.8M $101.9M $27.1M $9.9M $14.8M $3.7M
Business Acquisitions $0 $0 $8.2M $483.0K $0
Net Cash from Investing Activities $-24.8M $-3.1M $50.6M $-232.9M $156.2M $-114.7M $-104.8M $27.3M
Financing Activities
Dividends Paid
Stock Repurchases
Net Cash from Financing Activities $28.5M $6.9M $911.0K $270.5M $329.2M $303.7M $158.6M $88.8M
Net Change in Cash $-43.7M $-60.1M $-91.0M $-87.1M $373.1M $46.8M $-34.1M $50.0M
Free Cash Flow $-75.6M $-69.2M $-170.3M $-226.2M $-139.3M $-152.1M $-102.7M $-69.9M
← Newer Page 1 of 2 Older →